Amarin Corporation PLC (AMRN) Announces Notification of Patent Allowance for U.S. Application 13/349,150 Related to Vascepa and FDA Approved MARINE Indication
9/10/2012 9:05:52 AM
BEDMINSTER, N.J., and DUBLIN, Ireland, Sept. 10, 2012 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that the United States Patent and Trademark Office (USPTO) has published notification of a Notice of Allowance for U.S. Patent Application Serial Number 13/349,150. The application includes claims intended to protect the Vascepa™ (icosapent ethyl) indication approved in July 2012 by the U.S. Food and Drug Administration (FDA) based on Amarin's MARINE clinical trial results. A Notice of Allowance is issued after the USPTO makes a determination that a patent can be granted from an application.